Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses.
about
Self-assembling protein nanoparticles in the design of vaccinesThe Use of Synthetic Carriers in Malaria Vaccine DesignSynthetic self-adjuvanting glycopeptide cancer vaccinesStrategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen ModificationSynthetic Nanoparticles for Vaccines and ImmunotherapyImmunization of mice with formalin-inactivated spores from avirulent Bacillus cereus strains provides significant protection from challenge with Bacillus anthracis AmesFrom Immunologically Archaic to Neoteric Glycovaccines.Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems.Controlling the HIV/AIDS epidemic: current status and global challengesRelationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental designDevelopment of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.In situ re-endothelialization via multifunctional nanoscaffolds.Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles.Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine.A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge.Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides.A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice.Recombinant HPV16 E7 assembled into particles induces an immune response and specific tumour protection administered without adjuvant in an animal modelPermeation of antigen protein-conjugated nanoparticles and live bacteria through microneedle-treated mouse skin.Non-carrier nanoparticles adjuvant modular protein vaccine in a particle-dependent manner.Three steps to breaking immune tolerance to lymphoma: a microparticle approach.Synthesis and characterisation of self-assembled and self-adjuvanting asymmetric multi-epitope lipopeptides of ovalbumin.Amino-functionalized poly(L-lactide) lamellar single crystals as a valuable substrate for delivery of HPV16-E7 tumor antigen in vaccine development.A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.Cholesteryl Pullulan Encapsulated TNF-α Nanoparticles Are an Effective Mucosal Vaccine Adjuvant against Influenza VirusPotent Functional Immunogenicity of Plasmodium falciparum Transmission-Blocking Antigen (Pfs25) Delivered with Nanoemulsion and Porous Polymeric NanoparticlesRecent trends in vaccine delivery systems: A review.Expression, purification and characterization of a recombinant fusion protein based on the human papillomavirus-16 E7 antigenA therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease.Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic propertiesApplications of nanomaterials as vaccine adjuvants.Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospectsHepatitis C virus E2 protein encapsulation into poly d, l-lactic-co-glycolide microspheres could induce mice cytotoxic T-cell response.Self-assembly of hexahistidine-tagged tobacco etch virus capsid protein into microfilaments that induce IgG2-specific response against a soluble porcine reproductive and respiratory syndrome virus chimeric proteinDevelopment of Yersinia pestis F1 antigen-loaded microspheres vaccine against plague.Fabrication of nanoadjuvant with poly-ε-caprolactone (PCL) for developing a single-shot vaccine providing prolonged immunity.Novel adjuvants & delivery vehicles for vaccines development: a road aheadHarnessing Nanoparticles for Immunomodulation and VaccinesDendrimer-conjugated peptide vaccine enhances clearance of Chlamydia trachomatis genital infection.The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant.
P2860
Q26767097-04401BEF-DDD3-46A5-B731-9D2D5FB18059Q26777053-41CD173B-4002-4D2A-B831-649465F3B71FQ26777837-37E2A4F6-4EF3-4EC6-A6FB-FE1C5A193E30Q27001592-58D81768-C0B2-4BE7-BA57-3E240D9C11F7Q28085375-D2C0FB5B-713D-42A2-822B-4368F7D5581AQ28392659-661A14F2-11FA-4FF9-B36D-9C898473F121Q30238724-001D9EBA-B9A8-462C-B8A5-A51F41061E92Q30361646-4E6F4291-5413-462A-BE32-F8A356CF247AQ30420558-AD5FAAA6-0C50-48EC-8B9D-091525BBC052Q33779670-FEB2A8F4-B5AD-4876-ADBE-0103ED7420B1Q34341570-4D9C639C-798E-4B0A-BF12-35FD7C36FBDBQ34419883-485766A4-F050-48EB-9C52-24617EB88899Q34509079-7328E0FA-E02D-4FAF-B12C-DD97EBCD5A6BQ34633541-E55A580D-64C6-4F88-86BB-7E45C83DBCFAQ34700706-E7509000-F8E7-4D7C-B474-4A261F474CD1Q35034311-28ABBB06-4DF9-4EF5-9C92-F2469462620FQ35048518-B9E913D8-EF93-46D6-A3D2-0B9C0781E725Q35061200-C460563E-19B5-4C44-B3F7-B27DDF278F3FQ35090493-4B491088-B0F4-4EAE-BFD4-D062B5444F0DQ35165017-EC9FF62E-BAEC-4DF0-9E44-629272FF1388Q35328686-ABF7F1BC-35D0-452F-A31A-D178149C6EBCQ35423378-5B37C1F0-7102-4ADC-BFEB-1DD762D16705Q35605933-E28F5DA1-8400-4155-8A84-5AC074768C6EQ35853440-C45C1D17-D0AE-4B5F-B126-A00DEC4B175EQ36059495-F0632712-7166-41BF-87EF-ECDF764B827DQ36236790-11BA4783-CD51-4152-AEEA-6A58D3BC4863Q36300181-9CC581F8-9D22-411A-B450-5F2FFFC16619Q36662802-3D3DB820-2130-4095-9EB0-1AEDC9FDEC10Q37130755-15BA8EF2-EE1C-4FC6-A050-7C39795D6BF3Q37135480-43B3F4A3-66C9-4E45-8127-556222DC51D5Q37159697-5BBF0716-EEFE-4D2A-97C8-682F8E107811Q37286061-054A0A0B-2B79-4D46-92DC-FB6BA341C54DQ37354264-3592F93C-91D0-46CD-8C6F-38F4B23C41EFQ37449926-86BC0688-763B-47A1-91E4-731D3782A894Q37588454-5D992DF3-1D51-4ADA-A842-F426EFA584DFQ37591932-F0095ED0-EC51-45DC-AAEA-57C4F85E8947Q37592383-595FF01B-B55E-426A-B8DB-13311AAC5B2AQ37727724-BBF734C6-42F9-4470-A9DE-EE95E8853CDDQ37834084-BF6426D7-D932-498D-88CD-DA81E26FED19Q37956385-D6F7E92E-4D12-452A-AF65-01B6DC09571B
P2860
Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Nano-microparticles as immune ...... he resultant immune responses.
@en
Nano-microparticles as immune ...... he resultant immune responses.
@nl
type
label
Nano-microparticles as immune ...... he resultant immune responses.
@en
Nano-microparticles as immune ...... he resultant immune responses.
@nl
prefLabel
Nano-microparticles as immune ...... he resultant immune responses.
@en
Nano-microparticles as immune ...... he resultant immune responses.
@nl
P2093
P2860
P356
P1476
Nano-microparticles as immune ...... he resultant immune responses.
@en
P2093
Amit Kumar
Moses O Oyewumi
Zhengrong Cui
P2860
P304
P356
10.1586/ERV.10.89
P577
2010-09-01T00:00:00Z